Four-year outcomes from the US Early Access Program for arimoclomol in Niemann-Pick disease type C (NPC) have been published in Molecular Genetics and Metabolism, the sponsor, Zevra Therapeutics, announced on August 3, 2026. The programme, registered on ClinicalTrials.gov as NCT04316637 by Zevra Denmark and first posted on March 20, 2020, enrolled 109 participants at 14 US sites, 53 of them adults (48.6 per cent). Seventy-one participants (65.1 per cent) also took miglustat, and mean exposure to arimoclomol was 820 days. Mean total scores on the 5-domain NPC Clinical Severity Scale (5DNPCCSS) were reported as relatively stable over time, with comparable trends on the rescored 4-domain version and safety observations consistent with the drug's established profile. The journal article was not publicly reachable at the time of writing; the figures above are those in the sponsor's announcement, and the same dataset was presented by the site investigators, led by Elizabeth Berry-Kravis of Rush University Medical Center, in posters at the 22nd Annual WORLDSymposium in San Diego in February 2026.
This is an expanded access cohort, not a controlled trial: everyone enrolled received arimoclomol, alongside whatever routine care they were already having, and assessments were made during ordinary clinic visits rather than on a fixed research schedule. The registration record shows the entry terms: a confirmed diagnosis of NPC1 or NPC2, at least one neurological symptom, age two or above, and US residence, with treatment continuing at the treating physician's judgement. Arimoclomol was approved by the US Food and Drug Administration on September 20, 2024, under the brand name Miplyffa, for use in combination with miglustat for neurological manifestations of NPC in adults and children aged two and older.
For readers of this section, the adult data are the point of interest. NPC in adults presents in clinic with cognitive change, speech and swallowing difficulty and movement problems, and cognition is one of the five domains scored by the 5DNPCCSS. The rescored 4-domain scale, described in a 2025 Molecular Genetics and Metabolism paper, removes the cognition domain altogether and rescores swallowing, which is worth knowing when the two scales are quoted side by side. The investigators themselves state on their poster that there is no natural history data on disease progression in adult NPC, which limits any attempt to say what these adult scores would have looked like without treatment.
The arithmetic of follow-up is the main caution. The investigators report that 100 of the 109 exposed participants (92 per cent) had a baseline 5DNPCCSS score, that only the 23 participants (21.1 per cent) who enrolled in 2020 could have completed four years because enrolment was rolling, and that 20 participants completed both baseline and Year 4 assessments. They list heterogeneity of NPC, the small number with four-year data, inconsistent real-world reporting and selection bias among the limitations. They compare their result against a reported mean annual rise of 1.5 points on the 5DNPCCSS in untreated pediatric natural history data and an increase of one point or more as the threshold for clinically meaningful worsening. Scores do move on treatment: in the final results of the 48-month open-label extension of the phase 2/3 NPC-002 trial, published in 2025, mean 5DNPCCSS scores rose 3.2 points over 48 months among the 41 patients who entered, 29 of whom completed.